Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -140.36% is 547% below its 5-year average of -21.70%, around the middle of its 5-year range (-412.84%–-0.35%).
As of the fiscal period ended Tuesday, June 30, 2026. 49.80% above its 12-month average of -279.63%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -140.36%.
RETURN ON EQUITY (ROE)
-140.36%
RETURN ON EQUITY (ROE) AVG TTM
-279.63%
RETURN ON EQUITY (ROE) AVG 3Y
-144.28%
RETURN ON EQUITY (ROE) AVG 5Y
-21.70%
RETURN ON EQUITY (ROE) AVG 10Y
-8.11%
RETURN ON EQUITY (ROE) AVG 15Y
-5.38%
RETURN ON EQUITY (ROE) AVG 20Y
-2.88%
CURRENT VS TTM AVG
+49.80%
CURRENT VS 3Y AVG
+2.72%
CURRENT VS 5Y AVG
-546.70%
CURRENT VS 10Y AVG
-1629.87%
CURRENT VS 15Y AVG
-2507.67%
CURRENT VS 20Y AVG
-4775.99%
SECTOR MEDIAN · HEALTHCARE
-40.21%
median of 601 covered companies
CURRENT VS SECTOR MEDIAN
-249.07%
vs the sector median at left
Harvard Bioscience, Inc.
Market Cap
$39.10M
Return on Equity (ROE)
-140.36%
TTM Avg
-279.63%
3Y Avg
-144.28%
5Y Avg
-21.70%
Market Cap
$38.35M
Return on Equity (ROE)
-28.65%
TTM Avg
-189.41%
3Y Avg
-194.44%
5Y Avg
-158.64%
Market Cap
$39.90M
Return on Equity (ROE)
14.51%
TTM Avg
6.28%
3Y Avg
-34.57%
5Y Avg
-35.24%
Market Cap
$39.92M
Return on Equity (ROE)
-83.03%
TTM Avg
-44.32%
3Y Avg
5.07%
5Y Avg
17.23%
Market Cap
$37.28M
Return on Equity (ROE)
-160.05%
TTM Avg
-184.57%
3Y Avg
-168.71%
5Y Avg
-141.15%
Market Cap
$36.80M
Return on Equity (ROE)
-476.77%
TTM Avg
-979.99%
3Y Avg
-646.46%
5Y Avg
-421.61%
Market Cap
$41.78M
Return on Equity (ROE)
-66.47%
TTM Avg
-61.13%
3Y Avg
-30.57%
5Y Avg
-24.45%
Market Cap
$41.92M
Return on Equity (ROE)
-8.23%
TTM Avg
-18.98%
3Y Avg
-38.34%
5Y Avg
-43.89%
Market Cap
$36.25M
Return on Equity (ROE)
329.02%
TTM Avg
154.76%
3Y Avg
265.18%
5Y Avg
128.71%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Harvard Bioscience, Inc. (HBIO) | $39.10M | -140.36% | -279.63% | -144.28% | -21.70% |
| Incannex Healthcare Limited (IXHL)vs › | $38.35M | -28.65% | -189.41% | -194.44% | -158.64% |
| Nephros, Inc. (NEPH)vs › | $39.90M | 14.51% | 6.28% | -34.57% | -35.24% |
| Metagenomi, Inc. Common Stock (MGX)vs › | $39.92M | -83.03% | -44.32% | 5.07% | 17.23% |
| Edesa Biotech, Inc. (EDSA)vs › | $37.28M | -160.05% | -184.57% | -168.71% | -141.15% |
| Elicio Therapeutics, Inc. (ELTX)vs › | $36.80M | -476.77% | -979.99% | -646.46% | -421.61% |
| Filana Therapeutics, Inc. (FLNA)vs › | $41.78M | -66.47% | -61.13% | -30.57% | -24.45% |
| Precipio, Inc. (PRPO)vs › | $41.92M | -8.23% | -18.98% | -38.34% | -43.89% |
| Elutia Inc (ELUT)vs › | $36.25M | 329.02% | 154.76% | 265.18% | 128.71% |
| QT Imaging Holdings, Inc. (QTI)vs › | $35.80M | -819.34% | -116.46% | -74.90% | -96.78% |
ROE
-140.4%
ROA
-13.7%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -140.36% |
| 2026-03-31 | -97.39% |
| 2025-12-31 | -412.84% |
| 2025-09-30 | -382.68% |
| 2025-06-30 | -364.88% |
| 2025-03-31 | -391.31% |
| 2024-12-31 | -19.58% |
| 2024-09-30 | -21.80% |
| 2024-06-30 | -15.88% |
| 2024-03-31 | -12.69% |
| 2023-12-31 | -4.67% |
| 2023-09-30 | -4.39% |
| 2023-06-30 | -7.20% |
| 2023-03-31 | -2.71% |
| 2022-12-31 | -13.18% |
| 2022-09-30 | -9.57% |
| 2022-06-30 | -4.71% |
| 2022-03-31 | -8.51% |
| 2021-12-31 | -0.35% |
| 2021-09-30 | -2.42% |
| 2021-06-30 | -3.55% |
| 2021-03-31 | -5.14% |
| 2020-12-31 | -10.19% |
| 2020-09-30 | -8.61% |
| 2020-06-30 | -10.74% |
| 2020-03-31 | -8.99% |
| 2019-12-31 | -5.74% |
| 2019-09-30 | -3.78% |
| 2019-06-30 | -0.69% |
| 2019-03-31 | -2.20% |
| 2018-12-31 | -4.21% |
| 2018-09-30 | -5.91% |
| 2018-06-30 | -6.42% |
| 2018-03-31 | -4.87% |
| 2017-12-31 | -1.07% |
| 2017-09-30 | -4.14% |
| 2017-06-30 | -5.86% |
| 2017-03-31 | -6.51% |
| 2016-12-31 | -5.97% |
| 2016-09-30 | -26.52% |
| 2016-06-30 | -25.22% |
| 2016-03-31 | -23.37% |
| 2015-12-31 | -24.54% |
| 2015-09-30 | -2.03% |
| 2015-06-30 | -0.46% |
| 2015-03-31 | 0.26% |
| 2014-12-31 | 2.47% |
| 2014-09-30 | 1.67% |
| 2014-06-30 | 0.00% |
| 2014-03-31 | -1.25% |
| 2013-12-31 | -1.94% |
| 2013-09-30 | 0.12% |
| 2013-06-30 | 0.93% |
| 2013-03-31 | 1.86% |
| 2012-12-31 | 2.28% |
| 2012-09-30 | 1.90% |
| 2012-06-30 | 2.11% |
| 2012-03-31 | 2.72% |
| 2011-12-31 | 3.99% |
| 2011-09-30 | 5.48% |
| 2011-06-30 | 18.55% |
| 2011-03-31 | 19.62% |
| 2010-12-31 | 21.07% |
| 2010-09-30 | 23.32% |
| 2010-06-30 | 12.21% |
| 2010-03-31 | 10.03% |
| 2009-12-31 | 9.61% |
| 2009-09-30 | 7.68% |
| 2009-06-30 | 8.05% |
| 2009-03-31 | 4.71% |
| 2008-12-31 | 2.98% |
| 2008-09-30 | -1.92% |
| 2008-06-30 | -2.11% |
| 2008-03-31 | -1.52% |
| 2007-12-31 | -1.83% |
| 2007-09-30 | -3.22% |
| 2007-06-30 | -5.27% |
| 2007-03-31 | -3.27% |
| 2006-12-31 | -3.26% |
| 2006-09-30 | -7.35% |
| 2006-06-30 | -6.25% |
| 2006-03-31 | -45.24% |
| 2005-12-31 | -46.59% |
| 2005-09-30 | -34.05% |
| 2005-06-30 | -33.80% |
| 2005-03-31 | 2.49% |
| 2004-12-31 | 2.23% |
| 2004-09-30 | 2.92% |
| 2004-06-30 | 2.98% |
| 2004-03-31 | 3.43% |
| 2003-12-31 | 4.31% |
| 2003-09-30 | 1.64% |
| 2003-06-30 | 0.51% |
